Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- IBL Signs Licensing Contact with US Firm for Lung Cancer Type Identifying Antibody
October 25, 2011
- Daiichi Sankyo, AZ Apply for Additional Indication for Nexium for Prevention of GU, DU in Patients Given Low-Dose Aspirin
October 25, 2011
- Pfizer Japan to Split Up Domestic Manufacturing Sector to Establish New Company
October 25, 2011
- Top Drug Makers Poised to Announce 1st-Half Results: Patent Expirations Could Have Big Impact
October 25, 2011
- CMIC, Medipal Set Up Joint Venture for Orphan Drugs, Develop Alliance Model
October 24, 2011
- Sales Remain Unchanged due to Domestic Market Slump Affected by Quake: Chugai Jan-Sep 2011
October 24, 2011
- MSD, Mylan Terminate Promotional Contract for Lipovas and Renivase
October 24, 2011
- Astellas Recalls Tacrolimus in Japan, Europe After Dissolution Test Standards Unmet
October 24, 2011
- SymBio’s Bendamustine Gets NDA Approval in Taiwan
October 24, 2011
- US Baxter International Initiates PIII Clinical Trial for Blood Disorder Treatment Drug
October 24, 2011
- Otsuka Confirms Efficacy of Rotigotine for RLS in Domestic PIII Clinical Study
October 21, 2011
- Ono Upwardly Revises Sales Forecast Due to Main Product Growth
October 21, 2011
- Abbott to Separate into 2 Companies
October 21, 2011
- Chugai Tops Patent Asset Rankings, Teijin Jumps to Second Place
October 21, 2011
- No. of Latuda Prescriptions to Potentially Exceed Forecast: Nomura Securities
October 21, 2011
- Takeda Positions “Enbrel MRs” in Boosted Cooperation Efforts with Pfizer
October 20, 2011
- Otsuka to Set Up Joint Venture Company to Develop, Commercialize Pancreatic Islet Cells
October 20, 2011
- Growell to Introduce T-Point Service for Copayments of Ethical Drugs
October 20, 2011
- Sanofi Signs Comprehensive Contract with Kyoto Univ. on Life Science Research
October 19, 2011
- Takeda Initiates PIII Clinical Trials for Antidiabetic TAK-875 in US, Europe
October 19, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…